Cutia Therapeutics has announced that its Abbreviated New Drug Application (ANDA) for CU-40105, a self-developed topical finasteride spray for the treatment of androgenetic alopecia, has been accepted for review by the National Medical Products Administration (NMPA) of China. The company highlights that topical finasteride offers an alternative to oral formulations by enabling direct application to the scalp, potentially reducing systemic drug exposure and improving patient acceptance. There is no assurance that CU-40105 will ultimately be successfully developed and marketed. No grant or funding involving multiple organizations was mentioned in the announcement.